Elon's Haters Are About to Lose Their Minds...

Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

Mohd Haider
October 30, 2025

MediciNova Inc. (NASDAQ:MNOV) shares surged 87.39% to $2.23 in after-hours trading on Thursday.

Check out the current price of MNOV stock here

Publication Announcement

The California-based biopharmaceutical company said on Thursday that its research was published in the Journal of Atherosclerosis and Thrombosis, the official publication of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease.

The study, "Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis," was carried out in collaboration with a Japanese academic research group.

Research Results

According to the company, the study showed that MN-002, the primary metabolite of the oral bioavailable small molecule MN-001 (tipelukast), increased cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1.

See Also: Amazon Q3 FY2025 Earnings Call Transcript

Yuichi Iwaki, MediciNova president and CEO, said the collaborative research "provides mechanistic insight into how MN-001 and its metabolite MN-002 may influence cholesterol and lipid metabolism."

Clinical Development

Prior clinical research demonstrated that MN-001 significantly impacted patients with Type 2 diabetes and improved serum lipid profiles in patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).

The clinical-stage company is nearing completion of enrollment for a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD.

Stock Performance

MediciNova reported second-quarter earnings on Aug. 14, with a loss of 7 cents per share, beating the 10-cent loss analysts expected. Revenue totaled $134,600, exceeding expectations.

The company is scheduled to report third-quarter results Nov. 12.

MediciNova's 52-week range is $1.13 to $2.55, and its market capitalization stands at $57.87 million.

The stock is down 44.13% year to date.

Price Action: According to Benzinga Pro data, MediciNova closed Thursday's regular session at $1.19, up 0.85%.

Benzinga Edge Stock Rankings indicate that MNOV has a negative price trend across all time frames. Track the performance of other players in this segment.

Read Next:

  • Amazon, Netflix, Apple, Reddit And Coinbase: Why These 5 Stocks Are On Investors’ Radars Today

Photo Courtesy: meeboonstudio on Shutterstock.com

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Continue Reading...

Popular

Five 2026 vehicles you should absolutely wait for

Don’t buy that new car yet. If you can wait, you’ll have new 2026 model year options that aren’t out yet. Although some models barely change, others are completely redesigned and often get the latest features and improvements. Whether you’re interested in improved fuel economy, cutting-edge technology, or maybe just fresh and distinctive styling, there’s likely a car on the horizon that you’ll be interested in. To ensure you don’t miss out on the latest and greatest, the car experts at Edmunds highlight five vehicles you should consider waiting for.

Gold prices have tumbled from recent records. What's behind the losses?

NEW YORK (AP) — Less than a day after to another record high, prices for the precious metal plunged — marking the biggest sell-off in years.

The $43B Big Pharma Story is Starting Over-With a New Player - Ad

Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.

Warren Buffett's Berkshire Hathaway Bets Big On Consumer Brands Amid Economic Shifts

Warren Buffett and his successor Greg Abel have been directing Berkshire Hathaway towards consumer-centric investments throughout 2025.

Shaquille O'Neal's $180,000 Range Rover Stolen in Suspected Hacker Heist

The custom Range Rover belonging to Shaquille O'Neal has been stolen, reportedly due to a cyber attack.

Central Banks Are Buying More Gold Than Ever-And This U.S. Miner Is Ready to Oblige - Ad

Central banks are rapidly increasing their gold reserves-now nearly 20% of global assets. With rising demand and geopolitical pressure, U.S. gold supply is becoming more strategic than ever.

Donald Trump Jr.-Linked Drone Maker Unusual Machines Wins Major Pentagon Deal

Unusual Machines secures its largest Pentagon drone contract to date, with Trump Jr. serving as an adviser but not involved in the deal.

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.

Trump Signs Law to Launch Dollar 2.0 - Ad

Trump just signed law S.1582, unleashing the biggest money shift in 100+ years. For the first time since 1913, private firms - not the Fed - can mint a "Dollar 2.0." Treasury says it could drain $6.6T from banks and pay 10X current savings rates. Early investors in minting firms could see 40X returns by 2032.

Trump Warns Supreme Court Tariff Ruling Could 'Literally Destroy' The US: 'We'll Be Struggling For Years'

President Donald Trump warned that the U.S. economy would face significant challenges if the Supreme Court rules against the majority of the tariffs imposed this year.

Trump Commutes Former Rep. George Santos' Seven-Year Prison Term: '... Has Been Horribly Mistreated'

President Donald Trump announced on Friday that he commuted the prison sentence of former congressman George Santos (R-N.Y.), ordering his immediate release.

A Tiny Biotech Just Posted 10× Stronger Cancer Results - Ad

Early studies show this breakthrough delivery platform would make cancer treatments safer and more powerful. Now, with Big Pharma watching closely, investors are starting to take notice of what could be the next major biotech story.

Journalists turn in access badges, exit Pentagon rather than agree to new reporting rules

WASHINGTON (AP) — Dozens of reporters turned in access badges and exited the Pentagon on Wednesday rather than agree to government-imposed , pushing journalists who cover the American military further from the seat of its power. The U.S. government has called the new rules “common sense.”

From Ore to Gold Bars-This Nevada Mine Is Already Producing - Ad

Most juniors explore...Few actually produce. This one's already pouring gold thanks to infrastructure that would cost tens of millions to build today. With major land holdings and room to scale, it's one to watch.

Trump's $8.5 Billion Deal With Australia Challenges Chinese Dominance

Trump and Albanese signed a partnership to secure critical mineral supply chains and strengthen defense cooperation.

Is Big Pharma's Next Target Already in Play? - Ad

A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. With patented technology and promising early data, it's already catching the attention of Big Pharma.

Supreme Court will consider whether people who regularly smoke pot can legally own guns

WASHINGTON (AP) — said on Monday that it will consider whether people who regularly smoke marijuana can legally own guns, the latest firearm case to come before the court since .

Elizabeth Warren And Adam Schiff Introduce Senate Resolution Condemning Trump's Pardon Of Changpeng Zhao

Senators Elizabeth Warren (D-Mass.) and Adam Schiff (D-CA) are introducing a Senate resolution condemning President Donald Trump‘s pardon of Binance (CRYPTO: BNB) founder

The Wall Street Elites Are Moving Their Money Here - Ad

Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.

IonQ, D-Wave Quantum, Rigetti Computing Surge Over 11% Pre-Market: What's Going On?

Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) surged in premarket trading on Thursday.

Gold Bars Are Pouring, but This Miner is Still Priced Like a Startup - Ad

You'd expect a gold miner with production, a full refinery, and big-name investors to be trading at a premium. But this one? It's still under $1

Trump's Radical Plans for the Dollar - Ad

The Fed just slashed rates... yet mortgages have already soared higher. Meanwhile, Trump has his own plan for the dollar - a radical upgrade to our currency, already moving more money than Visa and Mastercard combined. Tech investor Eric Wade calls it the "Smart Dollar."

Krispy Kreme (DNUT) Stock Is Surging Wednesday: What's Going On?

Shares of Krispy Kreme are surging Wednesday, lifted by a wave of renewed retail investor interest in meme stocks.

Elon's Haters Are About to Lose Their Minds... - Ad

Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.

LendingTree CEO and founder Doug Lebda dies in ATV accident

NEW YORK (AP) — LendingTree CEO and founder Doug Lebda died in an an all-terrain vehicle accident over the weekend, the online loaning platform said Monday.

IonQ Shares Are Trading Lower Monday: What's Going On?

IonQ shares were trading higher Monday but have since reversed and began trading lower.

The $43B Big Pharma Story is Starting Over-With a New Player - Ad

Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.

Vietnam’s love affair with gas bikes is colliding with a new electric reality

HANOI, Vietnam (AP) — Vietnam is split between two visions: the rumbling, reliable gas-powered motorbikes that now rule the roads, and sleek, silent electric bikes the government says are its future.

NFL owners approve sale of 10% of the New York Giants to Julia Koch and her family

NEW YORK (AP) — NFL owners voted to approve the to Julia Koch and her family, Commissioner Roger Goodell said Wednesday.

Central Banks Are Buying More Gold Than Ever-And This U.S. Miner Is Ready to Oblige - Ad

Central banks are rapidly increasing their gold reserves-now nearly 20% of global assets. With rising demand and geopolitical pressure, U.S. gold supply is becoming more strategic than ever.

Microsoft's quarterly sales and profit surge, beating Wall Street expectations

REDMOND, Wash. (AP) — Microsoft on Wednesday reported its quarterly sales grew 18% to $77.7 billion.

Trump Signs Law to Launch Dollar 2.0 - Ad

Trump just signed law S.1582, unleashing the biggest money shift in 100+ years. For the first time since 1913, private firms - not the Fed - can mint a "Dollar 2.0." Treasury says it could drain $6.6T from banks and pay 10X current savings rates. Early investors in minting firms could see 40X returns by 2032.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright technicaltrading.org
Privacy Policy | Terms of Service